tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

SUPN Stock Latest News

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Press ReleasesSupernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
10h ago
SUPN
Salesforce downgraded, Charter upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Salesforce downgraded, Charter upgraded: Wall Street’s top analyst calls
9d ago
AR
MS
Piper downgrades Supernus to Neutral on slower Qelbree growth
PremiumThe Fly
Piper downgrades Supernus to Neutral on slower Qelbree growth
9d ago
SUPN
Supernus downgraded to Neutral from Overweight at Piper Sandler
PremiumThe Fly
Supernus downgraded to Neutral from Overweight at Piper Sandler
9d ago
SUPN
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
PremiumPress Releases
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
22d ago
SUPN
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
PremiumPress ReleasesSupernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
1M ago
SUPN
Supernus announces FDA acceptance of SPN-830 apomorphine infusion device NDA
Premium
The Fly
Supernus announces FDA acceptance of SPN-830 apomorphine infusion device NDA
1M ago
SUPN
Supernus raises 2024 sales outlook to $600M-$625M from $580M-$620M
Premium
The Fly
Supernus raises 2024 sales outlook to $600M-$625M from $580M-$620M
1M ago
SUPN
Supernus reports Q2 adjusted operating earnings $45.5M vs. $10M last year
PremiumThe Fly
Supernus reports Q2 adjusted operating earnings $45.5M vs. $10M last year
1M ago
SUPN
SUPN Earnings this Week: How Will it Perform?
PremiumPre-Earnings
SUPN Earnings this Week: How Will it Perform?
2M ago
SUPN
Supernus resubmits SPN-830 NDA after addressing complete response letter
PremiumThe Fly
Supernus resubmits SPN-830 NDA after addressing complete response letter
2M ago
SUPN
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
PremiumPress Releases
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
2M ago
SUPN
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
PremiumPress ReleasesSupernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
2M ago
SUPN
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Premium
Press Releases
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
4M ago
SUPN
Supernus gives interim data on open-label Phase 2a study of SPN-817 in epilepsy
Premium
The Fly
Supernus gives interim data on open-label Phase 2a study of SPN-817 in epilepsy
4M ago
SUPN
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
PremiumPress Releases
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
4M ago
SUPN
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
PremiumPress Releases
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
4M ago
SUPN
Supernus sees FY24 revenue $580M-$620M, consensus $601.46M
PremiumThe Fly
Supernus sees FY24 revenue $580M-$620M, consensus $601.46M
4M ago
SUPN
Supernus reports Q1 EPS 0c, consensus 38c
PremiumThe Fly
Supernus reports Q1 EPS 0c, consensus 38c
4M ago
SUPN
M8 Pharmaceuticals signs licensing agreement with Supernus
PremiumThe FlyM8 Pharmaceuticals signs licensing agreement with Supernus
5M ago
SUPN
SUPN Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
SUPN Upcoming Earnings Report: What to Expect?
5M ago
SUPN
Supernus partners with Busy Philipps to shine spotlight on ADHD in women
Premium
The Fly
Supernus partners with Busy Philipps to shine spotlight on ADHD in women
5M ago
SUPN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >